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To the Editor
The novel corona virus pandemic has the 
world in its grip and infection with COVID-19 has 
proven to be beyond a pulmonary disease. There 
are pre-existing cardiac conditions predisposing 
to it and the cardiological manifestations of the 
disease are being increasingly recognised.
The previous viral pandemics and epidemics 
have shown that viral infections are more likely to 
occur in patients with underlying cardiovascular 
disease [1]. Viral myocarditis is a prominent in-
fectious-inflammatory disease reported with the 
previous corona virus epidemics [2, 3]. Even long-
term follow up of the survivors of the previous 
viral epidemics has documented cardiovascular 
and metabolic abnormalities [4].
The published medical literature on 
COVID-19 relevant to cardiology is summarised 
in Table 1. There is mounting evidence that 
underlying cardiovascular conditions lead to 
a higher likelihood of infection, more severe dis-
ease progression, and a greater risk for mortality 
from COVID-19. Also, studies evaluating patients 
with COVID-19 presenting with cardiac  injury 
show that they have a poorer outcome. It is im-
portant for physicians to realise the importance 
of cardiac disease as a risk factor and potential 
complication of the disease because this might 
help in improving the management and treatment 
of infected patients.
Early measurement of cardiac biomarkers 
(troponin and NT-pro BNP) of a suspected infected 
patient can help identify cardiac injury. However, 
it is important to realise that biomarkers of cardiac 
injury often rise in hospitalized patients and that 
its interpretation and actionability would require 
careful consideration. Electrocardiography (ECG) 
is instrumental in assessing for arrhythmia, and 
echocardiography (ECHO) is a convenient bedside 
test to assess for cardiac systolic and diastolic 
function. The other test for assessing cardiac 
function is a cardiac MRI. CT and Doppler may 
assist in detecting the thrombotic complications 
in a patient.
It is still not clear whether the cardiac man-
ifestations are because the cardiac myocytes are 
the primary target or secondary bystander. Min-
imally invasive autopsies from lung, heart, and 
other sites of COVID-19 patients have shown that, 
while the virus does have a predilection for the 
lungs, the infection also results in damage to the 
heart, vessels, liver, kidney, and other organs [5]. 
Cardiac manifestations are likely due to a multi-
factorial aetiology; the myocardial damage could 
be related to the direct effect of the virus or may 
occur indirectly with increased oxygen demands 
due to tachycardia and fever, and reduced oxy-
gen delivery due to hypotension and hypoxemia. 
Another possibility is that the enhanced inflam-
matory state can induce vascular inflammation, 
myocarditis, and cardiac arrhythmias [6]. The 
resulting cytokine storm can elicit activation of 
cells within pre-existing atherosclerotic lesions 
thus augmenting thrombotic risk and risk of 
ischemic syndromes. Moreover, microvascular 
activation by cytokines can cause myocardial 
injury along with harm to other organ systems [7]. 
Besides these causes, the possible impacts of the 
drugs currently used to treat COVID-19 cannot 
be ignored. Some of the drugs that are frequently 
used to manage these cases are known to prolong 
the QT interval and can have a proarrhythmic pro-
pensity resulting in cardiac complications [8, 9].
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As the pandemic progresses, our knowledge 
on this novel infection will evolve. We have 
sufficient evidence of an increased severity of 
COVID-19 infection in patients with cardiac 
diseases and more mortality in patients with 
COVID-19 related cardiac failure and myocar-
ditis. It is important to alert clinicians of this 
because it would aid in the timely diagnosis of 
the cardiac complications. It is also important to 
acknowledge our poor understanding of the exact 
pathogenesis because currently, the possible role 
of angiotensin receptors and the possible long-
term effects of this virus are still to be assessed. 
Trials proving an optimal management strategy 
have not yet been completed, therefore, the best 
management that can currently be offered is of 
a supportive nature. Thus, constant physician vig-
ilance of the clinical presentation of such patients 
can help in reducing morbidity and mortality 




1. Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle 
East respiratory syndrome coronavirus (MERS-CoV): a sys-
tematic review and meta-analysis. Int J Infect Dis. 2016; 49: 
129–133, doi: 10.1016/j.ijid.2016.06.015, indexed in Pubmed: 
27352628.
2. Fung G, Luo H, Qiu Ye, et al. Myocarditis. Circ Res. 2016; 
118(3): 496–514, doi: 10.1161/CIRCRESAHA.115.306573, in-
dexed in Pubmed: 26846643.
3. Alhogbani T. Acute myocarditis associated with novel Mid-
dle East respiratory syndrome coronavirus. Ann Saudi Med. 
2016; 36(1): 78–80, doi: 10.5144/0256-4947.2016.78, indexed 
in Pubmed: 26922692.
4. Wu Qi, Zhou L, Sun X, et al. Altered lipid metabolism in re-
covered SARS patients twelve years after infection. Sci Rep. 
2017; 7(1): 9110, doi: 10.1038/s41598-017-09536-z, indexed in 
Pubmed: 28831119.
5. Yao XH, Li TY, He ZC, et al. A pathological report of three 
COVID-19 cases by minimal invasive autopsies. Zhonghua 
Bing Li Xue Za Zhi. 2020; 49(5): 411–417, doi: 10.3760/
cma.j.cn112151-20200312-00193, indexed in Pubmed: 
32172546.
6. Madjid M, Safavi-Naeini P, Solomon SD, et al. Potential ef-
fects of coronaviruses on the cardiovascular system: a review. 
JAMA Cardiol. 2020; 5(7): 831–840, doi: 10.1001/jamacar-
dio.2020.1286, indexed in Pubmed: 32219363.
7. Libby P. The heart in COVID-19: primary target or secondary 
bystander? JACC Basic Transl Sci. 2020; 5(5): 537–542, doi: 
10.1016/j.jacbts.2020.04.001, indexed in Pubmed: 32292847.
8. Sakabe M, Yoshioka R, Fujiki A. Sick sinus syndrome induced 
by interferon and ribavirin therapy in a patient with chronic 
hepatitis C. J Cardiol Cases. 2013; 8(6): 173–175, doi: 10.1016/j.
jccase.2013.08.002, indexed in Pubmed: 30534284.
9. Kochi AN, Tagliari AP, Forleo GB, et al. Cardiac and arrhythmic 
complications in patients with COVID-19. J Cardiovasc Elec-
trophysiol. 2020; 31(5): 1003–1008, doi: 10.1111/jce.14479, 
indexed in Pubmed: 32270559.
10. Aghagoli G, Gallo Marin B, Soliman LB, et al. Cardiac involve-
ment in COVID-19 patients: Risk factors, predictors, and com-
plications: A review. J Card Surg. 2020; 35(6): 1302–1305, doi: 
10.1111/jocs.14538, indexed in Pubmed: 32306491.
11. Shi S, Qin Mu, Shen Bo, et al. Association of cardiac injury 
with mortality in hospitalized patients with COVID-19 in Wu-
han, China. JAMA Cardiol. 2020; 5(7): 802–810, doi: 10.1001/
jamacardio.2020.0950, indexed in Pubmed: 32211816.
12. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for 
mortality of adult inpatients with COVID-19 in Wuhan, Chi-
na: a retrospective cohort study. Lancet. 2020; 395(10229): 
1054–1062, doi: 10.1016/S0140-6736(20)30566-3, indexed in 
Pubmed: 32171076.
13. Deng Y, Liu W, Liu K, et al. Clinical characteristics of fatal 
and recovered cases of coronavirus disease 2019 in Wuhan, 
China: a retrospective study. Chin Med J (Engl). 2020; 133(11): 
1261–1267, doi: 10.1097/CM9.0000000000000824, indexed in 
Pubmed: 32209890.
14. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 
deceased patients with coronavirus disease 2019: retrospec-
tive study. BMJ. 2020; 368: m1295, doi: 10.1136/bmj.m1295, 
indexed in Pubmed: 32234718.
15. Du Y, Tu L, Zhu P, et al. Clinical features of 85 fatal cases of 
COVID-19 from Wuhan. A retrospective observational study. 
Am J Respir Crit Care Med. 2020; 201(11): 1372–1379, doi: 
10.1164/rccm.202003-0543OC, indexed in Pubmed: 32242738.
16. Li X, Xu S, Yu M, et al. Risk factors for severity and mortality 
in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immu-
nol. 2020; 146(1): 110–118, doi: 10.1016/j.jaci.2020.04.006, 
indexed in Pubmed: 32294485.
17. Klok FA, Kruip MJ, van der Meer NJM, et al. Incidence of 
thrombotic complications in critically ill ICU patients with 
COVID-19. Thromb Res. 2020; 191: 145–147, doi: 10.1016/j.
thromres.2020.04.013, indexed in Pubmed: 32291094.
18. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting char-
acteristics, comorbidities, and outcomes among 5700 patients 
hospitalized with COVID-19 in the new york city area. JAMA. 
2020; 323(20): 2052–2059, doi: 10.1001/jama.2020.6775, in-
dexed in Pubmed: 32320003.
19. Zeng JH, Liu YX, Yuan J, et al. First case of COVID-19 compli-
cated with fulminant myocarditis: a case report and insights. 
Infection. 2020; 48(5): 773–777, doi: 10.1007/s15010-020-
01424-5, indexed in Pubmed: 32277408.
20. Inciardi RM, Lupi L, Zaccone G, et al. Cardiac involvement in 
a patient with coronavirus disease 2019 (COVID-19). 
JAMA Cardiol. 2020; 5(7): 819–824, doi: 10.1001/jamacar-
dio.2020.1096, indexed in Pubmed: 32219357.
21. Cui Y, Tian M, Huang D, et al. A 55-day-old female infant 
infected with 2019 novel coronavirus disease: presenting with 
pneumonia, liver injury, and heart damage. J Infect Dis. 2020; 
221(11): 1775–1781, doi: 10.1093/infdis/jiaa113, indexed in 
Pubmed: 32179908.
22. Bemtgen X, Kruger K, Supady A, et al. First successful treat-
ment of COVID-19 induced refractory cardiogenic plus vaso-
plegic shock by combination of pVAD and ECMO — a case 
report. ASAIO J. 2020; 16.
